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RESULTS: Depending on the time horizon, Lasik saved
from 18 to 278 km of distance to care centres against
spectacles and from 405 to 1,436 km against CL. Time
spent to care for visual acuity was found similar between
Lasik and CL but up to 1180 additional hours were spent
by CL wearers. Lasik saved from 4.69 to 12.07 spectacles
and from 28 to 84 cleaning packs, 18 to 50 visits to the
optic centre in comparison to glasses and 41 to 117 visits
when compared to CL. Lasik saved 4.7 to 12.2 visits for
correcting VA versus glasses or CL. Lasik avoided 95 to
295 per 10,000 cases of CL-related keratitis. CL were al-
ways more costly than Lasik which was always more
costly than glasses. The difference between glasses and
Lasik were from €1,595 to €2,521, and savings were
from €2,277 to €7,905 in comparison to CL.
CONCLUSION: Our study found that the Lasik strategy
was cost saving in comparison to CL strategy and more
expensive than the glasses strategy, without accounting
for potential non-monetary benefits of Lasik over glasses.
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OBJECTIVE: Prostamides have recently been introduced
for the treatment of glaucoma patients. We wanted to un-
derstand and evaluate the effectiveness and cost of new
anti-glaucoma medications and study the potential cost-
savings role that newer therapies may play in the preven-
tion of glaucoma progression to blindness. In this study,
estimated effectiveness and costs of a prostamide and a
representative from another fairly new category of anti-
glaucoma medications, the combination products, were
compared from a payer perspective.
METHODS: A pharmacoeconomic model was con-
structed based on a three-month randomized controlled
efficacy trial comparing Lumigan (bimatoprost 0.03%, a
new synthetic prostamide) and Cosopt (a fixed combina-
tion product of timolol 0.5% and dorzolamide 2.0%).
The clinical trial evaluated the percent of patients achiev-
ing various target intraocular pressures (IOPs) through-
out the day, and the cost of treatment to achieve target
calculation was based on the estimated effectiveness
from the trial. Total expected annual treatment costs in-
cluded direct costs of both medications and ophthalmol-
ogy visits.
RESULTS: With bimatoprost, 30% of patients (N  27)
reached and maintained a target IOP  17 mm Hg for all
measurements throughout the day vs. 17% with the com-
bination product (N  15; p  .05). Average expected
annual treatment costs, incorporating the costs of treat-
ment success and failure (requiring additional medica-
tions and office visits) were €485 vs. €471 for bimato-
prost vs. the combination product, respectively. Cost-
effectiveness, calculated as medication cost/expected ef-
fectiveness, based on patients achieving a target IOP at
three months of  17 mm Hg, was €139 vs. €190 for bi-
matoprost vs. the combination product, respectively.
CONCLUSION: Annual expected treatment costs for
prostamides and combination products are similar. How-
ever, when cost-effectiveness is considered, due to a greater
percentage of glaucoma patients achieving ideal target
treatment goals with prostamides, prostamides appear to
be more cost-effective than combination products.
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OBJECTIVE: The objective was to describe the socio-
economic impact of age-related macular degeneration
(AMD) and to assess, on a yearly basis, its medical and
social costs.
METHODS: A multicenter observational study was car-
ried out in a sample of 105 patients. Two ophthalmic re-
ferral care centers participated in the study. All subse-
quent patients who consulted during a three-week period
were included provided they presented the following cri-
teria:  60 years of age; an exudative form of AMD with
a distance visual acuity in the best eye  0.5. Data col-
lected included clinical items, treatment, medical follow-
up and transportation costs. The impact of AMD on the
living conditions and welfare payments related to visual
impairment were also recorded. A payer perspective was
used. Age and severity of disease were examined as cost
factors.
RESULTS: Mean age was 79.3 years and ranged from
62.8 to 95. Median distance visual acuity in the best eye
was 0.16 and average length of evolution was 3.5 years.
Over a three-month period, patients had an average of
2.6 visits to the ophthalmologist. Thirty percent of the
patients received vascular medications and 72.4% had re-
ceived previous photocoagulation treatment. Only 10 %
had benefited from visual rehabilitation. Hospitalizations
were rare (3%). AMD annual cost per patient was
€3,872.99 [3,163.19; 4,582.80]. Fifty percent of this was
attributed to medical costs. Other major cost components
were home help at €904.94 [485.40; 1,324.33] and
transportation costs for care at €542.72 [154.28;
931.16]. Total cost increased with age and with the loss
of visual acuity.
CONCLUSION: This study assesses the cost of resources
consumed, and probably underestimates the burden of
AMD. Indeed, the need for assistance in every day life is
important. Related costs being supported by the patient,
the recourse to expensive aids is very limited.
